Octapharma locks in $1.5B first US factory after tax-incentive fight
Plus: Bristol Myers Squibb beats Q2 estimates, raises guidance again. The day's rules, money, and enforcement, sourced and tiered below.
Plus: Bristol Myers Squibb beats Q2 estimates, raises guidance again. The day's rules, money, and enforcement, sourced and tiered below.
|
American Health Intel
Rules · Money · Medicine · Decoded daily
|
| The Ledger |
Saturday, August 1, 2026 |
|
|
Octapharma locks in $1.5B first US factory after tax-incentive fight
|
|
Plus: Bristol Myers Squibb beats Q2 estimates, raises guidance again. The day's rules, money, and enforcement, sourced and tiered below.
|
|
|
Deal Confidence: High
Octapharma, the Swiss maker of plasma-derived critical care medicines, just locked in its first-ever US factory: 1.5 billion dollars in Rock Hill, South Carolina, and about 1,500 jobs.
The deal nearly died in a weeks-long fight between York County and Rock Hill over splitting tax incentives before the city council approved it 7-0 on July 24. Production targets the mid-2030s.
|
Why it matters
A major foreign drugmaker is building its first US factory, adding domestic capacity for plasma-derived medicines used in trauma and critical care. Watch whether the mid-2030s timeline holds and how the local tax fight resolves.
|
|
|
Earnings Confidence: High
Bristol Myers Squibb, the drugmaker behind Opdivo and Eliquis, beat Wall Street's second-quarter revenue estimate by more than a billion dollars and raised its full-year guidance for the second straight quarter.
Revenue hit 13 billion dollars, up 6%. The newer Growth Portfolio, including Opdivo Qvantig and Reblozyl, grew 15% and now makes up nearly 60% of total revenue as older drugs lose patent protection.
|
Why it matters
One of the largest US drugmakers is outgrowing patent losses on older products, a sign the broader branded-pharma sector's newer drug launches are gaining traction. Watch whether the Growth Portfolio keeps outpacing legacy drug declines.
|
|
|
Also today
Lilly and Resilience invest $750M in US GLP-1 manufacturing Read
argenx pays $2.2B, 86% premium, for Forte Biosciences Read
FRONTIER SCAN: Vendor ransomware breach exposes 442,000+ patients Read
|
349 Records | $19.7B Enforcement | 17 Deadlines | 104 Rules |
|
|
Pick your field on the site and every story tells you what it means for you.
|
|
Reply to this email and tell us what you want covered. We read everything.
|
|
We show our work. We score our own calls.
News and analysis, not legal, medical, coding, or investment advice.
You subscribed at americanhealthintel.com · Unsubscribe
|
|